Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy
Immune-related adverse events (irAEs) can impair the effectiveness and safety of immune checkpoint inhibitors (ICIs) and restrict the clinical applications of ICIs in oncology. The predictive biomarkers of irAE are urgently required for early diagnosis and subsequent management. The exact mechanism...
Saved in:
Main Authors: | Xiujing He (Author), Jing Yu (Author), Hubing Shi (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
by: Jiqiao Yang, et al.
Published: (2019) -
Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma
by: Shanshan Yu, et al.
Published: (2021) -
Immune Checkpoint Molecules and Cancer Immunotherapy
by: Alexandr V. Bazhin
Published: (2019) -
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
by: Zoe Apalla, et al.
Published: (2021) -
Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
by: Rita Pimenta, et al.
Published: (2021)